Пожалуйста, подождите, мы загружаем данные графика
Novo Nordisk A/S сообщество
About Novo Nordisk A/S
What is Novo Nordisk A/S?
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
The current price of Novo Nordisk A/S in the market is 3 435,86 ₽, with a 24-hour trading volume of 30,71B ₽. The asset's market cap is 15,23T ₽, after moving 0.58% in the last day.
Tokenized Novo Nordisk A/S is trading at 3 545,24 ₽, with a tokenized market cap of 290,9M ₽ and a 24-hour trading volume of 78,72M ₽. The tokenized asset has moved 2.15% in the past 24 hours.